|
Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). |
|
|
Stock and Other Ownership Interests - Novasenta |
Consulting or Advisory Role - Aduro Biotech; Bristol-Myers Squibb; EMD Serono; Macrogenics; Merck; Novasenta; Numab; Pfizer; Sanofi; Zymeworks |
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Olympus |
|
|
No Relationships to Disclose |
|
|
Employment - Johns Hopkins Hospital |
Stock and Other Ownership Interests - Oncospace; Pistevo Health |
Honoraria - Sanofi/Regeneron |
Consulting or Advisory Role - Pinnacle Biologics; Tactile Medical |
Research Funding - Toshiba; Vibrent Health |
Patents, Royalties, Other Intellectual Property - Filed under Hopkins, we have several patents related to mobile informatics solutions |
Other Relationship - EPIC (I) |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Consulting or Advisory Role - Bayer; Rakuten Medical |
Research Funding - AstraZeneca; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - U Penn Olympus |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Abbvie; Intersect ENT |
|
|
Consulting or Advisory Role - MacroGenics |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Regeneron; Stryker |
Research Funding - Bristol Myers Squibb Foundation |
|
|
Honoraria - BioNTech; CUE Biopharma; Merck |
Consulting or Advisory Role - GlaxoSmithKline |
Research Funding - Bristol-Myers Squibb; Exelixis |
Travel, Accommodations, Expenses - Blueprint Medicines; GlaxoSmithKline; Merck; Pfizer |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Gilead Sciences (I); Johnson & Johnson (I); Lilly (I) |
Consulting or Advisory Role - Athenex; Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
Consulting or Advisory Role - Aduro Biotech; ALX Oncology; Celgene; CUE Biopharma; Debiopharm Group; IO Biotech; Ipsen; Macrogenics; Maverick Therapeutics; Merck; Nanobiotix; Oncolys BioPharma; Rakuten Medical |
Research Funding - Aduro Biotech (Inst); Bristol Myers (Inst); CUE Biopharma (Inst); Exelixis (Inst); Formation Biologics (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Debiopharm Group; Merck |